Source comparison
Kisspeptin Oral vs Injectable: Detailed Comparison
The following table summarizes the key differences between kisspeptin oral vs injectable formulations across pharmacokinetic, practical, and research application dimensions. Bioavailability 3–8% (most studies report <5% or undetectable plasma levels) 85–95% (S
This comparison does not assign a generated winner or score.
- The following table summarizes the key differences between kisspeptin oral vs injectable formulations across pharmacokinetic, practical, and research application dimensions.
- Bioavailability
- 3–8% (most studies report <5% or undetectable plasma levels)
- 85–95% (SC), 100% (IV)
- Injectable delivers 10–30× higher systemic exposure per mg administered
- Time to Peak Plasma Concentration
- Not applicable. Plasma concentrations typically below detection threshold
- 30–60 min (SC), 5–15 min (IV)
- Injectable produces predictable pharmacokinetics; oral does not
- GnRH/LH Pulse Induction
- No measurable effect in human trials at doses up to 10 mg
- Dose-dependent LH increase within 30–90 min at doses ≥0.1 nmol/kg
- Only injectable has demonstrated reproducible neuroendocrine effects
- Typical Research Dose
- 1–10 mg (7,700–77,000 nmol). Still ineffective
- 0.1–4.0 nmol/kg (approximately 7–280 nmol for 70 kg subject)
- Oral requires 100–1,000× higher doses and still fails to match injectable efficacy
- Ease of Administration
- No injection required; no reconstitution; stable at room temperature in capsule form
- Requires sterile reconstitution with bacteriostatic water; subcutaneous injection technique; refrigeration at 2–8°C post-reconstitution
- Oral is more convenient but pharmacologically inert in most subjects
- Cost per Effective Dose
- High cost per mg, but no effective dose has been established in humans
- Moderate cost; effective doses well-characterized
- Injectable is cost-effective per reproducible hormonal response; oral has no established effective dose